Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 26, 2023 |
Pediatric Exclusivity (PED) | Nov 26, 2023 |
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
2
United States
2
Japan
1
South Africa
1
Mexico
1
Australia
1
Slovenia
1
Lithuania
1
Hungary
1
Croatia
1
Brazil
1
Portugal
1
Cyprus
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
RS
1
China
1
EA
1
Canada
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic